When and How to Treat Superficial and Muscle-Invasive Bladder Cancer

European Urology

Volumn 52, Issue 6, 2007, Pages 1554-1557

  Zlotta, Alexandre R ^a  

^a Murray Koffler Urologic Wellness Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CARCINOMA IN SITU; EDITORIAL; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT PLANNING; TUMOR VOLUME;

CARCINOMA IN SITU; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; LYMPH NODE EXCISION; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 35948964793     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.09.033     Document Type: Editorial

References (14)

1. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
2. Schned A.R., Andrew A.S., Marsit C.J., Zens M.S., Kelsey K.T., and Karagas M.R. Survival following the diagnosis of noninvasive bladder cancer: WHO/International Society of Urological Pathology versus WHO classification systems. J Urol 178 (2007) 1196-1200
3. Gofrit O.N., Pode D., Lazar A., Katz R., and Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 49 (2006) 303-307
4. Palou Redorta J., Schatteman P., Huguet Pérez J., et al. Intravesical instillations with bacillus Calmette-Guérin for the treatment of carcinoma in situ involving prostatic ducts. Eur Urol 49 (2006) 834-838
5. Harland S.J., Kynaston H., Grigor K., et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol 178 (2007) 807-813
6. Guy L., Savareux L., Molinié V., Botto H., Boiteux J.-P., and Lebret T. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?. Eur Urol 50 (2006) 516-520
7. Fahmy N.M., Mahmud S., and Aprikian A.G. Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur Urol 50 (2006) 1176-1182
8. Karakiewicz P.I., Shariat S.F., Palapattu G.S., et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 50 (2006) 1254-1262
9. Sherif A., Garske U., de la Torre M., and Thörn M. Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancer. Eur Urol 50 (2006) 83-91
10. Liedberg F., and Månsson W. Lymph node metastasis in bladder cancer. Eur Urol 49 (2006) 13-21
11. Pectasides D., Pectasides M., and Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Eur Urol 48 (2005) 60-68
12. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 48 (2005) 202-206
13. David K.A., Milowsky M.I., Ritchey J., Carroll P.R., and Nanus D.M. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 178 (2007) 451-454
14. Sternberg C.N., Donat S.M., Bellmunt J., et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69 (2007) 62-79